ACT 2001

Drug Profile

ACT 2001

Alternative Names: ACT2001; CryoIT; Dendritic cell based cryoimmunotherapy

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Haakon Ragde Foundation
  • Developer Alden Cancer Therapy II; Haakon Ragde Foundation; Norwegian Radium Hospital
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 03 Jul 2018 ACT 2001 is still in clinical trials for Prostate cancer in Norway, the Philippines and in USA
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease) in Norway (Intratumoural, Injection)
  • 01 Jun 2018 Interim adverse events data from a phase I trial in Prostate cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top